Auregen BioTherapeutics - Ownership and Business Overview

Life ScienceCompany

Auregen BioTherapeutics Ownership

Who owns Auregen BioTherapeutics?

Auregen BioTherapeutics is owned by Gurnet Point Capital. It was acquired on December 1, 2016.

Is Auregen BioTherapeutics PE-backed?

Yes. Auregen BioTherapeutics is owned by private equity investor Gurnet Point Capital.

Auregen BioTherapeutics Business Overview

Where is Auregen BioTherapeutics headquartered?

Auregen BioTherapeutics is headquartered in Cambridge, Massachusetts.

What sector is Auregen BioTherapeutics in?

Auregen BioTherapeutics is a life science company.

Life Science M&A Summary in 2016

Out of 60 sectors in the Mergr database, life science ranked 8 in number of deals in 2016. The largest life science acquisition in 2016 was Baxalta - which was acquired by Shire for $32.0B.

Join Mergr to view all 295 acquisitions of life science companies in 2016, including 33 acquisitions by private equity firms, and 262 by strategics.

Auregen BioTherapeutics

Auregen BioTherapeutics, Inc.

55 Cambridge Parkway,
Cambridge, Massachusetts 02142
United States,
www.auregen.bio

Auregen BioTherapeutics is a biotechnology company translating pioneering 3D bioprinting technology for innovative treatments for patients with rare disorders. Auregen BioTherapeutics is based in Cambridge, Massachusetts.


 Subscribe to unlock this and 207,390
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 200K M&A Transactions
  • 203K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 81K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.